A B7-Cd28 Family Based Signature Demonstrates Significantly Different Prognoses and Tumor Immune Landscapes in Lung Adenocarcinoma

International Journal of Cancer- United States

doi 10.1002/ijc.31764

Full Text

Abstract

Available in

Categories

Cancer Research

Date

September 17, 2018

Authors

Publisher

Wiley

Related search

The Third Group of the B7-Cd28 Immune Checkpoint Family: HHLA2, TMIGD2, B7x, and B7-H3

Immunological Reviews

English

A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2

Clinical Cancer Research

Cancer Research

English

Decoding Tumor Mutation Burden and Driver Mutations in Early Stage Lung Adenocarcinoma Using CT‐based Radiomics Signature

Thoracic Cancer

Respiratory Medicine

English

A Robust Signature Based on Autophagy-Associated LncRNAs for Predicting Prognosis in Lung Adenocarcinoma

BioMed Research International

Molecular Biology

English

B7-H2 Is a Costimulatory Ligand for CD28 in Human

Infectious Diseases

English

A PD-L2-based Immune Marker Signature Helps to Predict Survival in Resected Pancreatic Ductal Adenocarcinoma

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

Identification of a Multidimensional Transcriptome Prognostic Signature for Lung Adenocarcinoma

Journal of Clinical Laboratory Analysis

Medical Laboratory Technology

Clinical Biochemistry

Occupational Health

English

Comprehensive Analysis of Prognostic Immune‐related Genes in the Tumor Microenvironment of Lung Adenocarcinoma

English

Cross-Linking the B7 Family Molecule B7-Dc Directly Activates Immune Functions of Dendritic Cells

Journal of Experimental Medicine

English